Last reviewed · How we verify
NYESO-1c259 T cells
At a glance
| Generic name | NYESO-1c259 T cells |
|---|---|
| Sponsor | Adaptimmune |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- CT Antigen TCR-redirected T Cells for Ovarian Cancer. (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NYESO-1c259 T cells CI brief — competitive landscape report
- NYESO-1c259 T cells updates RSS · CI watch RSS
- Adaptimmune portfolio CI